An announcement from CV Sciences Inc (CVSI) is now available.
CV Sciences, Inc. has expanded its portfolio by acquiring Elevated Softgels, a premier softgel manufacturer, and making it a wholly owned subsidiary. This strategic move, completed on May 13, 2024, involved a $100,000 cash payment and over 17 million restricted shares of CV Sciences common stock to the sellers. Additional payments are tied to future revenues, with potential earn-out amounts based on post-acquisition net revenue performance. The agreement also imposes certain restrictions on stock sales and competitive activities post-acquisition.
For detailed information about CVSI stock, go to TipRanks’ Stock Analysis page.
